Brief: Nextcure Inc- Entered Into A Sales Agreement For Common Stock Of Upto $75 Million
NextCure Inc expected to post a loss of 59 cents a share - Earnings Preview
Brief: NextCure Reports Q4 2020 Financial Results
Brief: Nextcure Inc Provides An Update On Clinical Trial Program For Nc318
Brief: Nextcure Reports Third Quarter 2020 Financial Results
Brief: Nextcure Reports Second Quarter 2020 Financial Results
NASDAQ RESUMED AT 09:50 AM
NASDAQ RESUMED AT 09:43 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:38 AM
Brief: Nextcure Provides Interim Update Of Phase 2 Portion Of Monotherapy Phase Trial, Announces Departure Of Chief Medical Officer
NextCure: Stops testing drug candidate in lung, ovarian cancer; shares fall
Brief: Nextcure Initiates Phase 1/2 Clinical Study Of NC410, A Novel Immunomedicine, For Solid Tumors
Brief: Nextcure Presents Biomarker Data And Updated Clinical Results From Phase 1 Portion Of Its Nc318 Clinical Trial
Brief: NextCure Reports Qtrly Earnings Per Share Diluted $ 0.33
Brief: NextCure To Temporarily Delay Starting NC318 Combination Clinical Trial In Lung Cancer
Brief: On Jan. 10, NextCure And Eli Lilly Notified Lilly's Termination Of Research & Development Collaboration Agreement
Live Markets U.s.: 2019 IPO market: The good, the bad, and the ugly
Brief: Nextcure Announces Public Offering Of 4.08 Mln Common Shares Priced At $36.75 per Share
Brief: Nextcure Announces Proposed Public Offering Of 3.2 Mln Common Stock Shares